Skip to main content
SpringerLink
Log in

Clinical Use of Polymyxin B

  • Chapter
  • First Online:
Polymyxin Antibiotics: From Laboratory Bench to Bedside

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1145))

Abstract

Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin). However, since the latter is administered as a prodrug, there are major pharmacokinetic differences between both polymyxins that may potentially determine different clinical and microbiological outcomes. Studies addressing clinical or microbiological outcomes in patients treated with polymyxin B for MDR or XDR GNB are reviewed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kwa A, Kasiakou SK, Tam VH, Falagas ME (2007) Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti-Infect Ther 5(5):811–821. https://doi.org/10.1586/14787210.5.5.811

    Article  CAS  PubMed  Google Scholar 

  2. Landman D, Georgescu C, Martin DA, Quale J (2008) Polymyxins revisited. Clin Microbiol Rev 21(3):449–465. https://doi.org/10.1128/cmr.00006-08

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yuan Z, Tam VH (2008) Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs 17(5):661–668. https://doi.org/10.1517/13543784.17.5.661

    Article  CAS  PubMed  Google Scholar 

  4. Zavascki AP, Goldani LZ, Li J, Nation RL (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60(6):1206–1215. https://doi.org/10.1093/jac/dkm357

    Article  CAS  PubMed  Google Scholar 

  5. Nation RL, Velkov T, Li J (2014) Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59(1):88–94. https://doi.org/10.1093/cid/ciu213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wertheim H, Van Nguyen K, Hara GL, Gelband H, Laxminarayan R, Mouton J et al (2013) Global survey of polymyxin use: a call for international guidelines. J Glob Antimicrob Resis 1(3):131–134. https://doi.org/10.1016/j.jgar.2013.03.012

    Article  Google Scholar 

  7. Nandha R, Sekhri K, Mandal AK (2013) To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B. Indian J Crit Care Med 17(5):283–287. https://doi.org/10.4103/0972-5229.120319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zavascki AP (2011) Dose adjustment of polymyxins for renal insufficiency. Antimicrob Agents Chemother 55(10):4940. https://doi.org/10.1128/aac.05080-11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zavascki AP (2014) Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside. Expert Rev Anti-Infect Ther 12(5):531–533. https://doi.org/10.1586/14787210.2014.902307

    Article  CAS  PubMed  Google Scholar 

  10. Falagas ME, Bliziotis IA, Tam VH (2007) Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 29(1):9–25. https://doi.org/10.1016/j.ijantimicag.2006.08.024

    Article  CAS  PubMed  Google Scholar 

  11. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A (2006) The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 4(2):138–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA (2007) Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 30(4):315–319. https://doi.org/10.1016/j.ijantimicag.2007.05.017

    Article  CAS  PubMed  Google Scholar 

  13. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP (2011) Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 66(1):175–179. https://doi.org/10.1093/jac/dkq390

    Article  CAS  PubMed  Google Scholar 

  14. Rigatto MH, Ribeiro VB, Konzen D, Zavascki AP (2013) Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Infection 41(2):321–328. https://doi.org/10.1007/s15010-012-0349-z

    Article  CAS  PubMed  Google Scholar 

  15. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM et al (2004) Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54(2):566–569. https://doi.org/10.1093/jac/dkh369

    Article  CAS  PubMed  Google Scholar 

  16. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH (2011) Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 55(10):4844–4849. https://doi.org/10.1128/aac.01728-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS (2008) Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61(6):1369–1375. https://doi.org/10.1093/jac/dkn128

    Article  CAS  PubMed  Google Scholar 

  18. Sekhri K, Nandha R, Mandal A, Bhasin D, Singh H (2013) Parenteral polymyxins: assessing efficacy and safety in critically ill patients with renal dysfunction. Indian J Pharmacol 45(6):608–611. https://doi.org/10.4103/0253-7613.121373

    Article  PubMed  PubMed Central  Google Scholar 

  19. Barbier F, Andremont A, Wolff M, Bouadma L (2013) Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 19(3):216–228. https://doi.org/10.1097/MCP.0b013e32835f27be

    Article  PubMed  Google Scholar 

  20. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 54(5):670–680. https://doi.org/10.1093/cid/cir934

    Article  CAS  PubMed  Google Scholar 

  21. Zavascki AP, Carvalhaes CG, Picao RC, Gales AC (2010) Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti-Infect Ther 8(1):71–93. https://doi.org/10.1586/eri.09.108

    Article  CAS  PubMed  Google Scholar 

  22. Ouderkirk JP, Nord JA, Turett GS, Kislak JW (2003) Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 47(8):2659–2662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Crusio R, Rao S, Changawala N, Paul V, Tiu C, van Ginkel J et al (2014) Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scand J Infect Dis 46(1):1–8. https://doi.org/10.3109/00365548.2013.844350

    Article  PubMed  Google Scholar 

  24. Dubrovskaya Y, Chen TY, Scipione MR, Esaian D, Phillips MS, Papadopoulos J et al (2013) Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 57(11):5394–5397. https://doi.org/10.1128/aac.00510-13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Elias LS, Konzen D, Krebs JM, Zavascki AP (2010) The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65(10):2231–2237. https://doi.org/10.1093/jac/dkq285

    Article  CAS  PubMed  Google Scholar 

  26. Mostardeiro MM, Pereira CA, Marra AR, Pestana JO, Camargo LF (2013) Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother 57(3):1442–1446. https://doi.org/10.1128/aac.01329-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS (2009) Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65(4):431–434. https://doi.org/10.1016/j.diagmicrobio.2009.07.018

    Article  CAS  PubMed  Google Scholar 

  28. Ramasubban S, Majumdar A, Das PS (2008) Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J Crit Care Med 12(4):153–157. https://doi.org/10.4103/0972-5229.45074

    Article  PubMed  PubMed Central  Google Scholar 

  29. Furtado GH, Gales AC, Perdiz LB, Santos AF, Medeiros EA (2011) Prevalence and clinical outcomes of episodes of ventilator-associated pneumonia caused by SPM-1-producing and non-producing imipenem-resistant Pseudomonas aeruginosa. Rev Soc Bras Med Trop 44(5):604–606

    Article  PubMed  Google Scholar 

  30. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR et al (2013) Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57(4):524–531. https://doi.org/10.1093/cid/cit334

    Article  CAS  PubMed  Google Scholar 

  31. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL et al (2008) Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47(10):1298–1304. https://doi.org/10.1086/592577

    Article  CAS  PubMed  Google Scholar 

  32. WSY S, Li J, Porter CJ, Nation RL, Patel K, McIntosh MP (2013) Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob Agents Chemother 57(10):5087–5095. https://doi.org/10.1128/aac.01127-13

    Article  Google Scholar 

  33. Gontijo AV, Gregoire N, Lamarche I, Gobin P, Couet W, Marchand S (2014) Biopharmaceutical characterization of nebulized antimicrobial agents in rats. 2. Colistin. Antimicrob Agents Chemother 58(7):3950–3956. https://doi.org/10.1128/aac.02819-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J et al (2014) Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58(5):2570–2579. https://doi.org/10.1128/aac.01705-13

    Article  PubMed  Google Scholar 

  35. He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH (2013) Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents 42(6):559–564. https://doi.org/10.1016/j.ijantimicag.2013.07.009

    Article  CAS  PubMed  Google Scholar 

  36. Pereira GH, Muller PR, Levin AS (2007) Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 58(2):235–240. https://doi.org/10.1016/j.diagmicrobio.2007.01.008

    Article  CAS  PubMed  Google Scholar 

  37. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D et al (2010) Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 51(11):1238–1244. https://doi.org/10.1086/657242

    Article  CAS  PubMed  Google Scholar 

  38. Kuo SC, Lee YT, Yang SP, Chen CP, Chen TL, Hsieh SL et al (2012) Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study. Clin Microbiol Infect 18(9):870–876. https://doi.org/10.1111/j.1469-0691.2011.03682.x

    Article  CAS  PubMed  Google Scholar 

  39. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z et al (2008) Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 102(3):407–412. https://doi.org/10.1016/j.rmed.2007.10.011

    Article  PubMed  Google Scholar 

  40. Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R et al (2013) Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144(6):1768–1775. https://doi.org/10.1378/chest.13-1018

    Article  CAS  PubMed  Google Scholar 

  41. Goto M, Al-Hasan MN (2013) Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 19(6):501–509. https://doi.org/10.1111/1469-0691.12195

    Article  CAS  PubMed  Google Scholar 

  42. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW (2010) Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54(9):3717–3722. https://doi.org/10.1128/aac.00207-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, De Pascale G, Parisini A et al (2011) Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 139(11):1740–1749. https://doi.org/10.1017/s0950268810003055

    Article  CAS  PubMed  Google Scholar 

  44. Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M (2013) Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti-Infect Ther 11(10):1053–1063. https://doi.org/10.1586/14787210.2013.836057

    Article  CAS  PubMed  Google Scholar 

  45. Ng TM, Teng CB, Lye DC, Apisarnthanarak A (2014) A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 35(1):49–55. https://doi.org/10.1086/674387

    Article  PubMed  Google Scholar 

  46. Dortet L, Poirel L, Nordmann P (2014) Worldwide dissemination of the NDM-type carbapenemases in gram-negative bacteria. Biomed Res Int 2014:249856. https://doi.org/10.1155/2014/249856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796. https://doi.org/10.1016/s1473-3099(13)70190-7

    Article  PubMed  PubMed Central  Google Scholar 

  48. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ et al (2011) Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 55(12):5893–5899. https://doi.org/10.1128/aac.00387-11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Pastewski AA, Caruso P, Parris AR, Dizon R, Kopec R, Sharma S et al (2008) Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann Pharmacother 42(9):1177–1187. https://doi.org/10.1345/aph.1K346

    Article  CAS  PubMed  Google Scholar 

  50. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH (2012) Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56(9):4625–4629. https://doi.org/10.1128/aac.00280-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH (2012) Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 56(11):5724–5727. https://doi.org/10.1128/aac.01333-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Barber AE, Norton JP, Spivak AM, Mulvey MA (2013) Urinary tract infections: current and emerging management strategies. Clin Infect Dis 57(5):719–724. https://doi.org/10.1093/cid/cit284

    Article  PubMed  PubMed Central  Google Scholar 

  53. Giua R, Pedone C, Cortese L, Antonelli Incalzi R (2014) Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature. Infection 42(1):199–202. https://doi.org/10.1007/s15010-013-0507-y

    Article  CAS  PubMed  Google Scholar 

  54. Suzuki Y, Toyota S, Katoh S, Fukushi Y, Orikasa S, Majima K (1989) Clinical effects of intravesical instillation of polymyxin B in patients with acute cystitis. Hinyokika Kiyo Acta Urologica Japonica 35(4):593–596

    CAS  PubMed  Google Scholar 

  55. Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R et al (2009) Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 9(4):245–255. https://doi.org/10.1016/s1473-3099(09)70055-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Jin L, Li J, Nation RL, Nicolazzo JA (2009) Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob Agents Chemother 53(10):4247–4251. https://doi.org/10.1128/aac.00485-09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Jin L, Li J, Nation RL, Nicolazzo JA (2011) Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob Agents Chemother 55(2):502–507. https://doi.org/10.1128/aac.01273-10

    Article  CAS  PubMed  Google Scholar 

  58. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39(9):1267–1284. https://doi.org/10.1086/425368

    Article  PubMed  Google Scholar 

  59. Gigliotti F, Hendley JO, Morgan J, Michaels R, Dickens M, Lohr J (1984) Efficacy of topical antibiotic therapy in acute conjunctivitis in children. J Pediatr 104(4):623–626

    Article  CAS  PubMed  Google Scholar 

  60. Williams L, Malhotra Y, Murante B, Laverty S, Cook S, Topa D et al (2013) A single-blinded randomized clinical trial comparing polymyxin B-trimethoprim and moxifloxacin for treatment of acute conjunctivitis in children. J Pediatr 162(4):857–861. https://doi.org/10.1016/j.jpeds.2012.09.013

    Article  CAS  PubMed  Google Scholar 

  61. Drehobl M, Guerrero JL, Lacarte PR, Goldstein G, Mata FS, Luber S (2008) Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa. Curr Med Res Opin 24(12):3531–3542. https://doi.org/10.1185/03007990802583845

    Article  CAS  PubMed  Google Scholar 

  62. Rahman A, Rizwan S, Waycaster C, Wall GM (2007) Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children. Clin Ther 29(9):1950–1956. https://doi.org/10.1016/j.clinthera.2007.09.005

    Article  CAS  PubMed  Google Scholar 

  63. Gyde MC (1981) A double-blind comparative study of trimethoprim-polymyxin B versus trimethoprim-sulfacetamide-polymyxin B otic solutions in the treatment of otorrhea. J Laryngol Otol 95(3):251–259

    Article  CAS  PubMed  Google Scholar 

  64. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH (2013) Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13(4):328–341. https://doi.org/10.1016/s1473-3099(12)70322-5

    Article  PubMed  Google Scholar 

  65. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS et al (2009) Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360(1):20–31. https://doi.org/10.1056/NEJMoa0800394

    Article  PubMed  Google Scholar 

  66. Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-Grauls CM (2013) Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 57(7):3224–3229. https://doi.org/10.1128/aac.02634-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lubbert C, Faucheux S, Becker-Rux D, Laudi S, Durrbeck A, Busch T et al (2013) Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents 42(6):565–570. https://doi.org/10.1016/j.ijantimicag.2013.08.008

    Article  CAS  PubMed  Google Scholar 

  68. Oostdijk EA, Smits L, de Smet AM, Leverstein-van Hall MA, Kesecioglu J, Bonten MJ (2013) Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med 39(4):653–660. https://doi.org/10.1007/s00134-012-2761-3

    Article  CAS  PubMed  Google Scholar 

  69. Parchuri S, Mohan S, Cunha BA (2005) Extended spectrum beta-lactamase-producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B. Heart Lung 34(5):360–363. https://doi.org/10.1016/j.hrtlng.2004.11.001

    Article  PubMed  Google Scholar 

  70. Fitzpatrick MA, Esterly JS, Postelnick MJ, Sutton SH (2012) Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam. Ann Pharmacother 46(7–8):e17. https://doi.org/10.1345/aph.1R086

    Article  PubMed  PubMed Central  Google Scholar 

  71. Klick JM, du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS (1975) Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest 55(3):514–519. https://doi.org/10.1172/jci107957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL (2013) Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57(9):1300–1303. https://doi.org/10.1093/cid/cit453

    Article  CAS  PubMed  Google Scholar 

  73. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT (2012) Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65(1):80–87. https://doi.org/10.1016/j.jinf.2012.01.015

    Article  PubMed  Google Scholar 

  74. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA et al (2014) In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58(5):2740–2746. https://doi.org/10.1128/aac.02476-13

    Article  PubMed  PubMed Central  Google Scholar 

  75. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP (2014) Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43(4):349–352. https://doi.org/10.1016/j.ijantimicag.2013.12.002

    Article  CAS  PubMed  Google Scholar 

  76. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61(5):649–672. https://doi.org/10.1053/j.ajkd.2013.02.349

    Article  PubMed  Google Scholar 

  77. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM (2006) Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 40(11):1939–1945. https://doi.org/10.1345/aph.1H353

    Article  CAS  PubMed  Google Scholar 

  78. Weinstein L, Doan TL, Smith MA (2009) Neurotoxicity in patients treated with intravenous polymyxin B: two case reports. Am J Health Syst Pharm 66(4):345–347. https://doi.org/10.2146/ajhp080065

    Article  CAS  PubMed  Google Scholar 

  79. Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL (1968) Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med 68(2):318–327

    Article  CAS  PubMed  Google Scholar 

  80. Pohlmann G (1966) Respiratory arrest associated with intravenous administration of polymyxin B sulfate. JAMA 196(2):181–183

    Article  CAS  PubMed  Google Scholar 

  81. Wunsch H, Moitra VK, Patel M, Dzierba AL (2012) Polymyxin use associated with respiratory arrest. Chest 141(2):515–517. https://doi.org/10.1378/chest.11-1483

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245

    Article  CAS  PubMed  Google Scholar 

  83. Knueppel RC, Rahimian J (2007) Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect Dis 45(1):136–138. https://doi.org/10.1086/518706

    Article  PubMed  Google Scholar 

  84. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C et al (2012) Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 14(2):198–205. https://doi.org/10.1111/j.1399-3062.2011.00688.x

    Article  CAS  PubMed  Google Scholar 

  85. Heinonen OP, Slone D, Shapiro S (1977) Birth defects and drugs in pregnancy. Publishing Sciences Group, Littleton

    Google Scholar 

  86. Czeizel AE (2001) The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary. Pharmacoepidemiol Drug Saf 10(7):635–639. https://doi.org/10.1002/pds.635

    Article  CAS  PubMed  Google Scholar 

  87. Kazy Z, Puho E, Czeizel AE (2005) Parenteral polymyxin B treatment during pregnancy. Reprod Toxicol (Elmsford, NY) 20(2):181–182. https://doi.org/10.1016/j.reprotox.2005.03.004

    Article  CAS  Google Scholar 

  88. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL (2010) Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54(9):3783–3789. https://doi.org/10.1128/aac.00903-09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL (2015) New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70(12):3291–3297. https://doi.org/10.1093/jac/dkv267

  90. Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, Li J, Nation RL (2018) Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother 73(2):462–468. https://doi.org/10.1093/jac/dkx409

    Article  PubMed Central  Google Scholar 

  91. Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL et al (2012) Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis 74(3):213–223. https://doi.org/10.1016/j.diagmicrobio.2012.07.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Gales AC, Jones RN, Sader HS (2011) Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 66(9):2070–2074. https://doi.org/10.1093/jac/dkr239

    Article  CAS  PubMed  Google Scholar 

  93. Teng CB, Koh PT, Lye DC, Ang BS (2008) Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 31(1):80–82. https://doi.org/10.1016/j.ijantimicag.2007.08.004

    Article  CAS  PubMed  Google Scholar 

  94. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP et al (2005) Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49(9):3624–3630. https://doi.org/10.1128/aac.49.9.3624-3630.2005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33(9):960–967

    Article  CAS  PubMed  Google Scholar 

  96. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR et al (2013) Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 68(3):674–677. https://doi.org/10.1093/jac/dks437

    Article  CAS  PubMed  Google Scholar 

  97. Zavascki AP, Bulitta JB, Landersdorfer CB (2013) Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti-Infect Ther 11(12):1333–1353. https://doi.org/10.1586/14787210.2013.845523

    Article  CAS  PubMed  Google Scholar 

  98. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A et al (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58(4):2322–2328. https://doi.org/10.1128/aac.02166-13

    Article  PubMed  PubMed Central  Google Scholar 

  99. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E et al (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56(4):2108–2113. https://doi.org/10.1128/aac.06268-11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55(7):943–950. https://doi.org/10.1093/cid/cis588

    Article  CAS  PubMed  Google Scholar 

  101. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K et al (2011) Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17(12):1798–1803. https://doi.org/10.1111/j.1469-0691.2011.03514.x

    Article  CAS  PubMed  Google Scholar 

  102. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P et al (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57(3):349–358. https://doi.org/10.1093/cid/cit253

    Article  CAS  PubMed  Google Scholar 

  103. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care (London, UK) 11(2):R31. https://doi.org/10.1186/cc5713

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Service, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

    Maria Helena Rigatto

  2. Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

    Maria Helena Rigatto

  3. Post-Graduate Program in Health and Human Development, Universidade La Salle, Canoas, Brazil

    Diego R. Falci

  4. Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

    Diego R. Falci & Alexandre P. Zavascki

  5. Department of Internal Medicine, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    Alexandre P. Zavascki

Authors
  1. Maria Helena Rigatto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diego R. Falci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandre P. Zavascki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandre P. Zavascki .

Editor information

Editors and Affiliations

  1. Biomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Clayton Campus, Melbourne, VIC, Australia

    Jian Li

  2. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Melbourne, VIC, Australia

    Roger L. Nation

  3. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA

    Keith S. Kaye

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rigatto, M.H., Falci, D.R., Zavascki, A.P. (2019). Clinical Use of Polymyxin B. In: Li, J., Nation, R., Kaye, K. (eds) Polymyxin Antibiotics: From Laboratory Bench to Bedside. Advances in Experimental Medicine and Biology, vol 1145. Springer, Cham. https://doi.org/10.1007/978-3-030-16373-0_14

Download citation

Publish with us

Policies and ethics

Search

Navigation